Home >> Tag Archives: Biocept—

Tag Archives: Biocept—

Teneovita to market Biocept’s liquid biopsy services

Sept. 12, 2016—Biocept has announced a preferred-provider agreement with Teneovita Medical, a division of Teneovita Medical Innovations. Under the agreement, Teneovita will market and distribute Biocept’s Target Selector liquid biopsy testing services to major cancer hospitals, individual oncology practices, and integrative oncology centers. “With a focus on cancer solutions, Teneovita Medical is an ideal distributor to make our full range ...

Read More »

Liquid biopsy PD-L1 test, 8/16

August 2016—Biocept launched its CLIA-validated PD-L1 protein expression test, which uses Biocept’s proprietary, patented Target Selector platform with circulating tumor cells from a patient’s blood sample and can be used to detect and monitor PD-L1 protein expression throughout the course of a patient’s cancer therapy.

Read More »

Biocept, Baylor to develop ESR1 liquid biopsies

Dec. 29, 2015—Biocept will collaborate with Baylor College of Medicine to develop minimally invasive blood-based tests using the company’s circulating tumor cell and circulating tumor DNA molecular diagnostic assay platforms to detect mutations in the estrogen receptor gene (ESR1). “Biocept’s unique technology is incredibility sensitive and specific, and its dual approach using both CTCs and ctDNA to detect biomarker mutations ...

Read More »

c-MET biomarker, 9/15

Biocept launched its c-MET amplification detection test. This diagnostic assay, which uses a blood-based liquid biopsy, has the potential to help physicians identify patients who may be receptive to certain gastric and non-small cell lung cancer treatments.

Read More »

NSCLC blood-based liquid biopsy test

January 2015—Biocept launched its lung cancer liquid biopsy testing, performed at its CLIA-certified, CAP-accredited laboratory. The blood-based biomarker testing for non-small cell lung cancer, along with the previously commercialized breast cancer offering, provides options for health care professionals and researchers for when a tumor biopsy is not available or is unsafe to perform or when additional information is desired.

Read More »
X